Tricyclic compounds as selective muscarinic receptor antagonists. 3. Structure-selectivity relationships in a series of cardioselective (M2) antimuscarinics
摘要:
On the basis of the cardioselective muscarinic receptor antagonist AF-DX 116 (2), a series of 11-substituted pyridobenzodiazepinones (9-35) was prepared and screened for their binding affinity to muscarinic receptors located in cardiac (M2) and glandular (M3) tissue. The ratio of IC50 values of the test compounds in the two different tissues was taken as a measure of cardiac (M2) receptor selectivity. Qualitative structure-selectivity relationships point to the fact that it is the spatial orientation of the protonated side-chain nitrogen atom in relation to the tricycle that is the main determinant for receptor subtype recognition and hence is important for the achievement of cardiac (M2) selectivity.
ENGEL, WOLFHARD W.;EBERLEIN, WOLFGANG G.;MIHM, GERHARD;HAMMER, RUDOLF;TRU+, J. MED. CHEM., 32,(1989) N, C. 1718-1724
作者:ENGEL, WOLFHARD W.、EBERLEIN, WOLFGANG G.、MIHM, GERHARD、HAMMER, RUDOLF、TRU+
DOI:——
日期:——
US4971966A
申请人:——
公开号:US4971966A
公开(公告)日:1990-11-20
Tricyclic compounds as selective muscarinic receptor antagonists. 3. Structure-selectivity relationships in a series of cardioselective (M2) antimuscarinics
作者:Wolfhard W. Engel、Wolfgang G. Eberlein、Gerhard Mihm、Rudolf Hammer、Guenter Trummlitz
DOI:10.1021/jm00128a008
日期:1989.8
On the basis of the cardioselective muscarinic receptor antagonist AF-DX 116 (2), a series of 11-substituted pyridobenzodiazepinones (9-35) was prepared and screened for their binding affinity to muscarinic receptors located in cardiac (M2) and glandular (M3) tissue. The ratio of IC50 values of the test compounds in the two different tissues was taken as a measure of cardiac (M2) receptor selectivity. Qualitative structure-selectivity relationships point to the fact that it is the spatial orientation of the protonated side-chain nitrogen atom in relation to the tricycle that is the main determinant for receptor subtype recognition and hence is important for the achievement of cardiac (M2) selectivity.
Substituted pyrido(2,3-B) (1,4) benzodiazepin-6-ones, and medicaments
申请人:Karl Thomae GmbH
公开号:US04971966A1
公开(公告)日:1990-11-20
New substituted pyrido[2,3-b][1,4]benzodiazepin-6-ones suitable as vagal pacemakers for the treatment of bradycardias and bradyarrhythmias in human and veterinary medicine are described.